Hepatitis C Virus
Pharmasset and Roche Initiate Studies to Advance R7128 for HCV
Published in Hepatitis Weekly, July 23rd, 2007
Pharmasset, Inc. (NASDAQ:VRUS) announces the start of long-term chronic toxicology studies in two animal species as part of their collaboration with Roche for the development of R7128 for the treatment of hepatitis C virus (HCV). R7128 is currently being evaluated in a Phase 1 clinical trial. The primary objective of the chronic toxicology studies is to assess the safety of R7128 when given for six months. Roche triggered a $7.5 million milestone payment to Pharmasset by initiating these studies.
"As we progress the ongoing 14-day multiple ascending dose study of R7128, we are encouraged that Roche has initiated the long-term chronic toxicology studies in support of the...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
Source: Hepatitis Weekly (2007-07-23)
More Articles from Hepatitis Weekly
- Hepatitis B Virus
UCLA/VA develops tool to gauge quality of life of hepatitis B patients - Cancer Vaccines
Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2007 - Hepatitis B Virus
Abbott Announces Approval of First Fully-Automated Blood Screening Test for Hepatitis C Antibodies - Hepatitis C Virus
MIGENIX Releases CEO Message #21 - HIV/AIDS
Peregrine Pharmaceuticals Initiates Bavituximab Clinical Trial in HCV Patients Co-Infected With HIV - DNA Vaccines
Investigators at PowderJect Vaccines, Inc. release new data on DNA vaccines - More from this issue of Hepatitis Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
